Evidence map›Paper›PMID 36531117›Full record

ArticleInternational journal of nanomedicine2022

A Multifunctional Nano-Delivery System Against Rheumatoid Arthritis by Combined Phototherapy, Hypoxia-Activated Chemotherapy, and RNA Interference.

Xiangyu Li, Shixin Zhang, Miaomiao Zhang, Ge Li, Bo Yang, Xinyue Lu, Lesheng Teng, Youxin Li, Fengying Sun

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Nanoparticle Delivery Systems in Rheumatoid Arthritis: More Than Vehicles.Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Stimuli-Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiangyu Li *School of Life Sciences, Jilin University, Changchun, People's Republic of China.
Shixin Zhang *School of Life Sciences, Jilin University, Changchun, People's Republic of China.
Miaomiao ZhangSchool of Life Sciences, Jilin University, Changchun, People's Republic of China.
Ge LiSchool of Life Sciences, Jilin University, Changchun, People's Republic of China.
Bo YangSchool of Life Sciences, Jilin University, Changchun, People's Republic of China.
Xinyue LuSchool of Life Sciences, Jilin University, Changchun, People's Republic of China.
Lesheng TengSchool of Life Sciences, Jilin University, Changchun, People's Republic of China.ORCID 0000-0003-1623-5384
Youxin LiSchool of Life Sciences, Jilin University, Changchun, People's Republic of China.
Fengying SunSchool of Life Sciences, Jilin University, Changchun, People's Republic of China.ORCID 0000-0001-6199-9311
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Effective therapy for rheumatoid arthritis (RA) keeps a challenge due to the complex pathogenesis of RA. It is not enough to completely inhibit the process of RA with any single therapy method. The purpose of the research is to compensate for the insufficiency of monotherapy using multiple treatment regimens with different mechanisms. Material and Methods: In this study, we developed a new method to synthesize mesoporous silica nanoparticles hybridized with photosensitizer PCPDTBT (HNs). Branched polyethyleneimine-folic acid (PEI-FA) could be coated on the surface of HNs through electrostatic interactions. It simultaneously blocked the hypoxia-activated prodrug tirapazamine loaded into the mesopores and binded with Mcl-1 siRNA (siMcl-1) that interfered with the expression of the anti-apoptotic protein Mcl-1. Released from the co-delivery nanoparticles (PFHNs/TM) Tirapazamine and siMcl-1 upon exposure to acidic conditions of endosomes/lysosomes in activated macrophages. Under NIR irradiation, photothermal therapy and photodynamic therapy derived from PCPDTBT, hypoxia-activated chemotherapy derived from tirapazamine, and RNAi derived from siMcl-1 were used for the combined treatment for RA by killing activated macrophages. PEI-FA-coated PFHNs/TM exhibited activated macrophage-targeting characteristics, thereby enhancing the in vitro and in vivo NIR-induced combined treatment of RA. Results: The prepared PFHNs/TM have high blood compatibility (far below 5% of hemolysis) and ideal in vitro phototherapy effect while controlling the TPZ release and binding siMcl-1. We prove that PEI-FA-coated PFHNs/TM not only protect the bound siRNA but also are selectively uptaked by activated macrophages through FA receptor-ligand-mediated endocytosis, and effectively silence the target anti-apoptotic protein by siMcl-1 transfection. In vivo, PFHNs/TM have also been revealed to be selectively enriched at the inflammatory site of RA, exhibiting NIR-induced anti-RA efficacy. Conclusion: Overall, these FA-functionalized, pH-responsive PFHNs/TM represent a promising platform for the co-delivery of chemical drugs and nucleic acids for the treatment of RA cooperating with NIR-induced phototherapy.

Indexed as

Arthritis, RheumatoidNanoparticlesFolic AcidHumansHypoxiaMyeloid Cell Leukemia Sequence 1 ProteinNanoparticle Drug Delivery SystemPhototherapyPolymersRNA InterferenceRNA, Small InterferingThiadiazolesTirapazamineFolic AcidMyeloid Cell Leukemia Sequence 1 ProteinNanoparticle Drug Delivery Systempoly(2,6-(4,4-bis(2-ethylhexyl)-4H-cyclopenta(2,1-b-3,4-b0)dithiophene))-alt-4,7-(2,1,3-benzothiadiazole)PolymersRNA, Small InterferingThiadiazolesTirapazaminehypoxia-activated chemotherapynano-delivery systemphototherapyrheumatoid arthritisRNA interference

Identifiers

PMID36531117
PMCPMC9749419
OpenAlexW4311133611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.